Clinical Utility of in-vivo MRS Measurements of 2-Hydroxyglutarate in IDH-Mutated Gliomas

Keywords

although answering audience basic begins brain cancer care cell characteristics chemotherapy choline circles clear clinical completely correlated correlates correlation course criteria cycles death decrease decreased depending detect detection determine diagnosis diagram discovery disease dynamic eighteen enhancement enrolled enrollment established evaluation every evidence experimental fell flair fourth gadolinium giving goal good grade grow growth highest highly histogram hypothesis in vivo included indicated initial interval intervention investigated known largely marked mass measured measures mechanisms median medical metabolite mickey monitoring month months must mutated mutation neurological noticeable objective oncologists panel patient patients patterns peak period pope post press prior procedure production prognosis progression protocol questions radiation radiographic radiologists rapidly reduction referred reproduced reproducibility reproducible resolution resolved respond responded response retest rise rises role scanned seizures sensitive series several slab southwestern spectral stable subsequent subtypes suggesting supported surgeons surgical symptoms target thick third tissue transl treated treatment treatments tumor tumors undertaken underwent upper useful utility ward years